A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity

por Kim, Miriam Y., Jayasinghe, Reyka, Devenport, Jessica M., Ritchey, Julie K., Rettig, Michael P., O’Neal, Julie, Staser, Karl W., Kennerly, Krista M., Carter, Alun J., Gao, Feng, Lee, Byung Ha, Cooper, Matthew L., DiPersio, John F.
Publicado 2022

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies

por Xiang, Jingyu, Devenport, Jessica M., Carter, Alun J., Staser, Karl W., Kim, Miriam Y., O’ Neal, Julie, Ritchey, Julie K., Rettig, Michael P., Gao, Feng, Rettig, Garrett, Turk, Rolf, Lee, Byung Ha, Cooper, Matthew L., DiPersio, John F.
Publicado 2023